ChemoCentryx (ChemoCentryx) Cash, Cash Equivalents, Marketable Securities : $328.62 Mil (As of Jun. 2022)

View and export this data going back to 2012. Start your Free Trial

What is ChemoCentryx Cash, Cash Equivalents, Marketable Securities?

ChemoCentryx's quarterly cash, cash equivalents, marketable securities increased from Dec. 2021 ($264.49 Mil) to Mar. 2022 ($340.60 Mil) but then stayed the same from Mar. 2022 ($340.60 Mil) to Jun. 2022 ($328.62 Mil).

ChemoCentryx's annual cash, cash equivalents, marketable securities increased from Dec. 2019 ($172.79 Mil) to Dec. 2020 ($436.57 Mil) but then declined from Dec. 2020 ($436.57 Mil) to Dec. 2021 ($264.49 Mil).

ChemoCentryx Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for ChemoCentryx's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoCentryx Cash, Cash Equivalents, Marketable Securities Chart

ChemoCentryx Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

127.29

176.98

172.79

436.57

264.49

ChemoCentryx Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															312.60	269.43	264.49	340.60	328.62

ChemoCentryx Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

ChemoCentryx (NAS:CCXI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

ChemoCentryx Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of ChemoCentryx's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

ChemoCentryx (ChemoCentryx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ChemoCentryx Inc (NAS:CCXI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

835 Industrial Road, Suite 600, San Carlos, CA, USA, 94070

Website

https://www.chemocentryx.com

ChemoCentryx Inc is a biopharmaceutical company involved in the discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.

Executives

Susan M Kanaya	officer: SVP Finance, CFO & Secretary	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Thomas J. Schall	director, 10 percent owner, officer: President, CEO and Director	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Jennifer Lyn Herron	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James L Tyree	director	100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Yi Ching Yau	officer: SVP, Finance & Acctg Officer	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
David E. Wheadon	director	C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Tausif Butt	officer: EVP, Chief Operating Officer	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Thomas A. Edwards	director	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Markus J. Cappel	officer: CBO and Treasurer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Pui San Kwan	officer: Principal Acctg Officer	850 MAUDE AVENUE MOUNTAIN VIEW CA 94043
Rajinder Singh	officer: SVP, Research	C/O CHEMOCENTRYX, INC. 850 MAUDE AVE. MOUNTAIN VIEW CA 94043
Rita Jain	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027